| Prev Close | 49.91 |
| Open | 49.86 |
| Day Low/High | 49.51 / 49.88 |
| 52 Wk Low/High | 37.62 / 55.00 |
| Volume | 2.09M |
| Avg Volume | 1.74M |
Sanofi (SNY)
49.68
0.23
0.46
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 2.51B |
| Market Cap | 129.93B |
| EPS | 1.30 |
| P/E Ratio | 27.16 |
| Div & Yield | 1.17 (2.28%) |
2 Speculative Biotech Stocks for 2016
Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.
U.S. Carmakers Benefit the Most From Jump in European Car Sales
And four other things you need to know now.
Jim Cramer Sees a Deal on Priceline Stock, Likes Weyerhaeuser
TheStreet's Jim Cramer said to buy Priceline (PCLN) on the dip Monday while answering viewer questions from the floor of the New York Stock Exchange.
Closing Bell: Sanofi Falls on Weak Diabetes Sales; Crude Tops $46
Stocks ended the day lower in a quieter session of trading compared to Wednesday's blowout rally.
Building a Sweet 16 Portfolio, Part 1
Selection of stocks is tailor made for investor, given market parameters.
Sanofi, Marks & Spencer Offer European Value Says S&P Capital IQ
The European economy is growing and the volatility from the Greek exit drama is keeping a lid on stock valuations.
Here Are 3 Charts Showing You Why Illumina Is a Marvel
It's almost impossible to get too excited about its success.
Obamacare Ruling Means the Debate Is Over
As health-care stocks rally, it's time for politicians to move on.
What's So Great About an Up Opening?
Don't rely on Europe; it's too out of sync with U.S.
Here's What's Driving Biotech
And it's not the favorable macroeconomic climate.
Gilead May Be the Cure for the Blues
Gilead's Relative Strength Index slope is very strong.
Gilead May Be the Cure for the Blues
Gilead's Relative Strength Index slope is very strong.
That's Just What's Supposed to Happen
Stocks that stabilized yesterday were terrific today.
Growth Seekers Return
Investors are seeing growth today in three areas.
Picking Up Where We Left Off
Another quarter, another run to record highs.
Consider These Three French Companies
These firms offer strong dividends, cash flow and trailing 12-month sales.
The Day Ahead: Just Another Muted Monday
Welcome to another holiday-shortened week.
Is There Still a Play to Be Made on Regeneron?
An inverse head and shoulders pattern could soon develop.
Unilife Strutting Over Sanofi Deal
Syringe-seller Unilife is gaining momentum - and scaring the shorts - after signing a big deal with Sanofi, says Alan Shortall, CEO of Unilife.
Europe Makes a Comeback
When economic news is good, so are investment prospects
This Is Incredibly Bullish Behavior
Most stocks seem unable to stop once propelled higher.
Small IPOs Bring Risks
Gladstone Land, KaloBios Pharmaceuticals and Stemline Therapeutics plan to go public, IPO Desktop President Francis Gaskins isn't sure the risk is worth it.
Blown Away by Transports, Drugs
Not so much by the financials.
Don't Wait to Buy Wells Fargo, Sanofi
Jeanie Wyatt, CEO of South Texas Money Management, names her favorite stocks including Wells Fargo and Sanofi.
Europe: Down but Not Out
Despite the economic travails, it has companies that are doing well.
3 Cancer-Drug Stocks Look Strong
These drug companies addressing prostate cancer get high grades from my guru strategies.
Sour on Sanofi
This drugmaker has fallen from a nine-month high to a key support level in just five sessions.
Two Drug Stocks Offer Trade Setups
Forest Labs has potential volatility and high short interest, and Sanofi has crossed some key levels.
Buy SNY under $35
Stephanie Link, director of research for TheStreet, explains why Sanofi is an attractive investment under $35.
3 Stocks I Saw on TV, January 30
Dan Fitzpatrick examines three stocks viewed on Fast Money. Today's stocks include Sanofi-Aventis, Cypress Semiconductor and Biogen.
